{"id":"sunitinib-capecitabine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Hypertension"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Hand-foot syndrome"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sunitinib's inhibition of VEGFR and PDGFR leads to anti-angiogenic effects, while its inhibition of c-KIT can affect tumor growth. Capecitabine's conversion to 5-fluorouracil results in the inhibition of thymidylate synthase, leading to DNA damage and cell death in rapidly dividing cancer cells.","oneSentence":"Sunitinib inhibits multiple receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT, while Capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:45.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Renal cell carcinoma"},{"name":"Gastrointestinal stromal tumor"}]},"trialDetails":[{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT00961571","phase":"PHASE2","title":"Sunitinib and Capecitabine for First Line Colon Cancer","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2009-08","conditions":"Metastatic Colorectal Cancer","enrollment":50},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT02483247","phase":"PHASE1","title":"A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-09","conditions":"Cancer","enrollment":165},{"nctId":"NCT02921724","phase":"NA","title":"Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies.","status":"UNKNOWN","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-01-27","conditions":"Cancer, Oral Drug Administration","enrollment":40},{"nctId":"NCT00891878","phase":"PHASE2","title":"Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-08","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer","enrollment":12},{"nctId":"NCT00787787","phase":"PHASE2","title":"Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2008-09","conditions":"Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer","enrollment":41},{"nctId":"NCT00570908","phase":"PHASE2","title":"Brain Mets - Capecitabine Plus Sunitinib and WBRT","status":"TERMINATED","sponsor":"Baylor Breast Care Center","startDate":"2009-02","conditions":"Breast Cancer","enrollment":12},{"nctId":"NCT00662025","phase":"PHASE2","title":"Study Of Sunitinib With Capecitabine In Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-04","conditions":"Advanced/Metastatic Breast Cancer","enrollment":63},{"nctId":"NCT00555620","phase":"PHASE1","title":"Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-05","conditions":"Stomach Neoplasms","enrollment":76},{"nctId":"NCT01058044","phase":"NA","title":"Adherence to Oral Anticancer Treatment Using Electronic Monitoring System","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2009-07","conditions":"Cancer","enrollment":33},{"nctId":"NCT00246571","phase":"PHASE2","title":"Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Breast Neoplasms","enrollment":217},{"nctId":"NCT00435409","phase":"PHASE3","title":"A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-02","conditions":"Breast Neoplasms","enrollment":442},{"nctId":"NCT00373113","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-11","conditions":"Breast Neoplasms","enrollment":482},{"nctId":"NCT00777478","phase":"PHASE1","title":"Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2008-12","conditions":"Colorectal Cancer","enrollment":32},{"nctId":"NCT00618124","phase":"PHASE1","title":"A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-05","conditions":"Solid Tumors, Breast Cancer, Neoplasms","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":88,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sunitinib + Capecitabine","genericName":"Sunitinib + Capecitabine","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sunitinib inhibits multiple receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT, while Capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor. Used for Renal cell carcinoma, Gastrointestinal stromal tumor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}